Fortitude Biomedicines raises $13M in Seed funding to advance antibody-based therapies for autoimmune diseases and cancer, co-led by K2 Bio Partners and SHAC.
Amount Raised
$13 Million
Round Type
Seed
Investors
Description
Fortitude Biomedicines, Inc. announced the closing of a $13 million Seed financing to advance their novel antibody-based therapies. The funding will support their lead immune cell targeting biologic program through IND enabling studies. Co-led by K2 Bio Partners and Shanghai Healthcare Angel Capital, with participation from additional investors
Quick answer
Fortitude Biomedicines raised $13 Million in a Seed round, dated January 26, 2026. Investors: Shanghai Healthcare Angel Capital, Elikon Venture, Everjoy Fortune, Taihill Venture and K2 Bio Partners. Fortitude Biomedicines is based in Waltham, Massachusetts, United States.
- How much did Fortitude Biomedicines raise?
- Fortitude Biomedicines raised $13 Million in a Seed round on January 26, 2026.
- Who invested in Fortitude Biomedicines?
- Shanghai Healthcare Angel Capital, Elikon Venture, Everjoy Fortune, Taihill Venture and K2 Bio Partners are named as investors in this round.
- What does Fortitude Biomedicines do?
- Fortitude Biomedicines is a leading biopharmaceutical company focused on immune cell targeting biologics and molecular glue payload–enabled antibody–drug conjugates (ADCs) for the treatment of a wide range of autoimmune..
- Where is Fortitude Biomedicines based and how big is it?
- Fortitude Biomedicines is based in Waltham, Massachusetts, United States. Fundz records about 7 employees.
- Who are the decision-makers at Fortitude Biomedicines?
- Fundz holds 1 contact at Fortitude Biomedicines, including the Director of Operations & Corporate Development. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Fortitude Biomedicines that raised within 45 days of this round, from Fundz verified event records.
- Combat Medical raised $3.5M (Series A) on March 12, 2026.
- GenSight Biologics raised $2M (Post-IPO Equity) on March 10, 2026.
- Cognito Therapeutics raised $105M (Series C) on March 5, 2026.
- NexCure raised $19M (Series A) on March 5, 2026.
- Prolium Bioscience raised $50M (Series A) on March 5, 2026.
- Os Therapies raised $2M on March 4, 2026.
Who to call at Fortitude Biomedicines, and when
A new round usually means Fortitude Biomedicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Fortitude Biomedicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Fortitude Biomedicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Fortitude Biomedicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Fortitude Biomedicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Fortitude Biomedicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.